#opioid-crisis

#opioid-crisis

Carfentanil is a potent synthetic opioid linked to a significant rise in overdose deaths, emphasizing the dangers of counterfeit pills.

Mayor Lurie prioritizes law enforcement over Sup. Fielder's public-health approach to the opioid crisis.

Long Island businesses are placing anti-overdose medication Narcan behind counters to combat opioid overdoses.

New York City's public hospital system introduces a groundbreaking addiction treatment program in South Bronx modeled on successful Staten Island initiative.

California has made naloxone available to the public to combat opioid overdoses.

Psychedelics show promise in treating chronic pain, offering potential alternatives to traditional opioid treatments.

FDA approves non-opioid painkiller suzetrigine, marking a significant advancement in pain management amid the opioid crisis.

New methods might allow effective pain relief without the risk of opioid addiction.

Journavx, an FDA-approved painkiller, offers a non-addictive alternative to opioids, blocking pain signals directly at their source.

A court ruling temporarily protects 10 supervised drug consumption sites in Ontario, but long-term funding uncertainty poses risks to their operation.

Dr. Koka's clinics face ongoing scrutiny for high opioid prescriptions amid calls for operational changes from local officials.

Walgreens will pay $350 million to settle allegations of illegally filling opioid prescriptions.

Walgreens disclaims liability but aims to close opioid litigation and refocus on business.

Purdue Pharma and the Sackler family have settled lawsuits for $7.4 billion over the opioid crisis, marking a significant judicial outcome.

California now sells affordable opioid reversal drugs directly to consumers.

The program is focused on reducing opioid overdose deaths and ensuring accessibility.

Naloxone's approval without prescription aims at fighting the opioid crisis.

Webster Norton actively equips bartenders and servers with naloxone and fentanyl test strips, transforming them into de facto first responders to the opioid crisis.

Purdue Pharma's reorganization plan aims to address the opioid crisis while navigating ethical challenges surrounding their past misconduct.

McKinsey has settled a Justice Department investigation with a $650 million payment related to its work with Purdue Pharma during the opioid crisis.

A former McKinsey partner pleaded guilty to obstructing justice in relation to Purdue Pharma's opioid sales strategy.

McKinsey acknowledges wrongdoing and pays $650 million related to the opioid epidemic settlement over five years.

Deep brain stimulation may help reduce cravings in alcohol and opioid addicts by normalizing brain electrical rhythms.

Boston establishes the Family Overdose Support Fund, offering up to $5,000 for services to families affected by opioid overdose.

The fund addresses both immediate financial needs and long-term healing for grieving families.

Rural areas show rising overdose risks from prescription and synthetic opioids; inner city trends shift toward methadone overshadowing heroin use.

The tragic death of Martyn Pink underscores the urgent need for accessible mental health and addiction services.

Protests against planned closure of supervised drug consumption sites reflect concerns over rising overdose deaths in Ontario.

Ontario's new legislation to shut down supervised consumption sites is challenged for violating the Charter of Rights and for exceeding provincial authority.

Buprenorphine treatment significantly enhances patient retention in addiction recovery, as evidenced by a critical study conducted at Yale.

The Pitt explores the intersection of intense medical drama and the emotional experiences of patients and their families in emergency medicine.

The deaths related to denied health insurance claims highlight severe flaws in the American healthcare system, impacting patient outcomes adversely.

The opioid crisis highlights corporate corruption and the failures of a for-profit healthcare system that prioritizes profits over patient safety.

McKinsey is nearing a settlement over its role in the opioid crisis, negotiating a deferred prosecution agreement with a payout exceeding $600 million.

McKinsey & Co. will pay over $122 million to resolve a felony bribery probe linked to work in South Africa.